Robot-assisted laparoscopic surgery using DROP-IN radioguidance: first-in-human translation

Philippa Meershoek1,2 · Matthias N. van Oosterom1,2 · Hervé Simon3 · Laurent Mengus3 · Tobias Maurer4,5 · Pim J. van Leeuwen7 · Esther M. K. Wit2 · Henk G. van der Poel2 · Fijs W. B. van Leeuwen1,2

Received: 11 May 2018 / Accepted: 16 July 2018 / Published online: 27 July 2018
© The Author(s) 2018

Abstract
Purpose Radioguided surgery has been widely used for clinical procedures such as sentinel node resections. In the (robot-assisted) laparoscopic setting radioguidance is realized using laparoscopic gamma probes, which have limited maneuverability. To increase the rotational freedom, a tethered DROP-IN gamma probe was designed. Here we present the first in vivo feasibility study of this technology in prostate cancer patients.

Methods Ten patients scheduled for a sentinel node procedure received four injections into the prostate with (indocyanine green-)99mTc-nanocolloid and underwent preoperative imaging (lymphoscintigraphy and SPECT/CT). The DROP-IN probe was inserted via the assistant port, still permitting the insertion and usage of additional laparoscopic tools.

Results The sentinel nodes were resected using the da Vinci® Si robot under guidance of DROP-IN gamma tracing and fluorescence imaging. The surgeon was able to independently maneuver the DROP-IN probe using the ProGrasp® forceps of the da Vinci® robot and distinguish sentinel nodes from background signal (such as the injection site).

Conclusions Overall the DROP-IN design proves to be a valuable tool for robot-assisted radioguided surgery approaches.

Keywords Prostate cancer · Radioguided surgery · Robotic surgery · Sentinel lymph node · Gamma probe

Introduction
Within the concept of radioguided surgery, findings in preoperative nuclear medicine imaging, e.g. scintigraphy and single-photon emission computed tomography/ computed tomography (SPECT/CT), have been successfully translated to surgery. Such radioguided resections have been explored for a range of indications, tracers and isotopes [1]. Radioguidance is most routinely applied during sentinel lymph node (SN) identification with 99mTc-labeled radiocolloids (e.g. 99mTc-nanocolloid) [1]. Although a wide variety of intraoperative radioguidance modalities has been studied, such as mobile gamma cameras and freehandSPECT, the gamma-ray detection probe with its acoustic and numerical feedback still remains the leading intraoperative modality [1].

Evolutionary developments in the field of surgery have increasingly pushed towards minimally invasive approaches such as (robot-assisted) laparoscopic surgery. This shift resulted in the development of laparoscopic gamma probes, which essentially are elongated gamma probes that can be inserted through a trocar. While numerous sites use such probes during laparoscopic SN procedures of, for example, cervical cancer and prostate cancer [2, 3], the probe length and its pivot point in the trocar greatly decrease the degrees of freedom (DOF) available for probe placement to four DOF vs. six in open surgery [4]. This rotational impairment limits the identification of lesions (e.g. SNs generally harbor 1% of injected dose (ID)) when located in close vicinity to high background signals (e.g. during...
SN procedures the injection site harbors >90% of ID) [5, 6]. Additionally, blocking a trocar with this tool denies access of other tools (e.g. suction or tissue retrieval). In case of robot-assisted laparoscopic surgery, traditional radioguidance is further complicated by the fact that the surgeon is not present at the bedside, but performs surgery via the use of a distant console. Consequently, the surgical assistant has to perform gamma tracing under verbal guidance of the surgeon.

The emergence of fluorescence imaging cameras as an integrated tool during (robot-assisted) laparoscopic procedures, with the appealing real-time visual guidance they provide, is increasingly pushing surgeons away from the field of nuclear medicine. One may argue this is a potentially dangerous phenomenon given that clinical studies with hybrid tracers such as indocyanine green (ICG)–99mTc-nanocolloid, clearly indicate that fluorescence guidance cannot replace radioguidance, but rather complement it in a best-of-both-worlds scenario [7]. Nevertheless, during robot-assisted hybrid SN procedures, the above mentioned practical limitations of the laparoscopic gamma probe increasingly diminish its use during surgery. As a result, nuclear medicine findings are used for preoperative planning, fluorescence guidance for intraoperative SN identification and the laparoscopic gamma probe is generally used as back-up and ex vivo confirmatory modality [8]. To reintroduce the use of intraoperative radioguidance, and thus expand the market for (tracer) innovations in nuclear medicine, more practical laparoscopic gamma probe technologies need to become available.

Recently we reported on the development and preclinical evaluation of a tethered DROP-IN gamma probe technology [4]. In this study we report on the first-in-human experience with this technology during robot-assisted laparoscopic SN procedures of the prostate.

**Methods**

**Patients**

Ten patients with a Briganti nomogram-based [9] risk >5% of lymph node (LN) metastases were included. All patients were scheduled for robot-assisted radical prostatectomy (RARP), extended pelvic lymph node dissection (ePLND: all LNs around the external iliac artery and vein, the LNs within the obturator fossa, and the LNs surrounding the internal iliac artery) and SN removal. SN mapping was based on preoperative imaging (lymphoscintigraphy and SPECT/CT) acquired using either the hybrid ICG-99mTc-nanocolloid [8] agent or 99mTc-nanocolloid. To realize fluorescence guidance intraoperatively in the latter group free ICG (5 mg/mL ICG) was injected transperineal intraprostatis, approximately 15 min before the start of the surgical procedure. Informed consent was obtained from all individual participants included in the study. The study was approved by the local ethics committee (NL57838.031.16). Patient characteristics are shown in Table 1.

**Surgical (imaging) tools**

For the robot-assisted surgical procedure the da Vinci® Si (Intuitive Surgical Inc., Sunnyvale, CA, USA) with integrated Firefly™ fluorescence laparoscope (Intuitive Surgical Inc.) was used. For gamma tracing, a DROP-IN probe prototype (Eurorad S.A., Eckbolsheim, France) was used [4]. A sterile DROP-IN was inserted into the abdominal cavity either through or next to a trocar within the Alexis® port (Alexis...

---

**Table 1** Summary findings

| Characteristic                              | Value                             |
|--------------------------------------------|-----------------------------------|
| Patients included                          | 10                                |
| Age (years; mean ± SD (range))             | 68.9 ± 5.7 (59–77)                |
| Patients receiving tracer(s) (%)           |                                   |
| - ICG-99mTc-nanocolloid                    | - 5 (50%)                         |
| - 99mTc-Tc-nanocolloid + ICG               | - 5 (50%)                         |
| Total SN related hotspots on SPECT/CT      | 30                                |
| - Left                                     | 16                                |
| - Right                                    | 14                                |
| Total SNs specimens excised                | 35                                |
| - Left                                     | 18                                |
| - Right                                    | 17                                |
| Total SNs measured in vivo with DROP-IN probe | 20             |
| - External right (%)                       | 3 (15%)                           |
| - Internal right (%)                       | 0 (0%)                            |
| - Obturator right (%)                      | 4 (20%)                           |
| - Cloquet right (%)                        | 1 (5%)                            |
| - Presacral left (%)                       | 1 (5%)                            |
| - Other locations (%)                      | 11 (55%)                          |
| In vivo radioactivity                      |                                   |
| - DROP-IN median counts (range))          | 675 (200–2600)                    |
| Total SNs measured in vivo for fluorescence | 19*                             |
| - Fluorescent SNs (%)                      | 19 (100%)                         |
| Ex vivo radioactivity                      |                                   |
| - DROP-IN probe (median counts (range))    | 682 (89–7000)                     |
| - Neoprobe (median counts (range))         | 378 (33–14,000)                   |
| Total SNs measured ex vivo for fluorescence | 18*                             |
| - Fluorescent SNs (%)                      | 18 (100%)                         |
| Pathological examination (%)               |                                   |
| SNs found in excised SN specimens         | 60 (100%)                         |
| - SNs tumor positive                       | - 1 (1.7%)                        |
| LNs found in excised nonSN specimens      | 149 (100%)                        |
| - LNs tumor positive                       | - 0 (0%)                          |
| Resection status per patient (n = 10)      |                                   |
| R0                                         | 6 (60%)                           |
| R1                                         | 4 (40%)                           |
| Postoperative complications (%)            |                                   |
| Yes                                        | 6 (60%)                           |
| - Urinary retention                        | - 2 (20%)                         |
| - Urinary leakage                          | - 2 (20%)                         |
| - Urinary infection                        | - 1 (10%)                         |
| - Parastomal hernia                        | - 1 (10%)                         |
| No                                         | 4 (40%)                           |

*All SNs that were measured for fluorescence were fluorescent in- and ex-vivo. One patient did not receive free ICG, and in one patient the SN was not measured ex vivo.
laparoscopic system, Applied Medical Corp., Rancho Santa Margarita, CA, USA).

Surgical procedure

SPECT/CT images provided a roadmap wherein the tracer accumulating SNs were displayed in their anatomical context (Fig. 1) [8]. (Suspected) SN locations were then intraoperatively scanned with the DROP-IN, while the laparoscope was frequently switched between white light and fluorescence imaging. When SNs were located in a region with a high risk of surgical complications, the decision was made to leave these SNs in situ. The number and location of pre-, intra-, and postoperatively identified SNs were recorded, including fluorescent and radioactive status (Table 1). Prostatectomy followed the nodal dissection (both SN and ePLND).

Ex vivo, a conventional gamma probe (Neoprobe, Devicor Medical Products, Cincinnati, OH, USA) and an open surgery fluorescence camera (FIS-00 or PDE; Hamamatsu Photonics K.K., Hamamatsu, Japan) was used to validate tracer uptake.

Results

Intraoperative sentinel node identification

SPECT/CT revealed 30 SN-related hotspots and during surgery 35 SNs were excised using a combination of intraoperative DROP-IN radioguidance and fluorescence guidance (Table 1). Through the combination with the Alexis® port, the DROP-IN probe could remain in the patient during the complete nodal resection, while the surgical bedside assistant could still use a

![Fig. 2 Rotational freedom of the DROP-IN probe in vivo. (a) The da Vinci® ProGrasp® forceps was inserted from the lower left abdominally placed trocar. Arrows indicate the degrees of freedom. (b–g) The small gamma probe head connected to a flexible wire resulted in freely maneuvering the probe by the surgeon using the forceps](image-url)
grasper through the assistant trocar. With the articulated ProGrasp® forceps probe pick-up and placement could be realized without interference of the surgical assistant. Probe positioning was considered intuitive and benefited from a wide scanning range (0°–140°) (Figs. 2 and 3). A total of 45% of the removed SNs that were measured with the DROP-IN in vivo were located in regions classified as difficult for traditional laparoscopic gamma tracing: external, internal, obturator and cloquet region right, and presacral region left (Table 1). As the study was performed using both fluorescent and radioactive signals, the use of the DROP-IN was benchmarked against using the Firefly™ technology (Fig. 3).

No side effects were observed while using the DROP-IN intraoperatively. Postoperative complications did occur (Table 1), however, they were not related to the use of the SN-procedure or DROP-IN probe, indicating it is safe to use.

Pathological examination

From the 35 excised SN specimens one tumor positive SN was recovered (Table 1). The excised ePLND templates (excision of 149 additional LNs) did not yield positive LNs.

Discussion

Our feasibility study in prostate cancer patients underlines the ability of the DROP-IN technology to freely scan every direction in the abdominal cavity and supports the symbiotic use of gamma tracing and fluorescence imaging. The accuracy and convenience created by the DROP-IN technology increases the surgical implementation of nuclear medicine findings. In the patient bed (in the background), but autonomously positions the DROP-IN probe towards a SN. The DROP-IN console provides a radioactive count number and acoustic signal as read-out. (e) As insert the Firefly™ fluorescent image of the SN identified using the DROP-IN.
particular, it facilitates radioguidance concepts during (robot-assisted) laparoscopic surgery.

The difference between the number of SN-related hotspots and amount of excised SNs is most likely a consequence of cluster nodes. Previously we found that during nodal resections one hotspot on SPECT/CT often contains multiple LNs that only become distinguishable using intraoperative fluorescence guidance or following pathological examination of the excised tissue [8].

To date, radioguidance has proven itself to be the most sensitive surgical guidance modality, allowing gamma tracing even when fluorescence is not detectable [6]. Hence, in addition to advancing laparoscopic SN procedures, the DROP-IN probe technology also holds future promise for receptor targeted radioguidance procedures. An obvious example of such an emerging radioguidance procedure that could benefit from the DROP-IN to make it compatible with, for example, the robotic da Vinci® platform would be the tracing of prostate specific membrane antigen (PSMA) expressing nodal metastases using $^{99m}$Tc-PSMA-I&S [10]. As robot-assisted surgery is rapidly advancing beyond urology, likely the DROP-IN technology will support the translation/implementation of radioguidance in other indications.

**Conclusion**

Our clinical first-in-human feasibility study indicates the DROP-IN: (1) facilitated radioguided resections, (2) increased the autonomy of the operating surgeon, (3) enlarged the probe maneuverability and (4) left the assistant trocar free for the introduction of other surgical tools. Further studies aimed at evaluating the technology in the clinical setting, including $^{99m}$Tc-PSMA-I&S guided procedures, are ongoing.

**Funding** This research is funded by an NWO-STW-VIDI grant (STW BGT11272) and an NWO-TTW-VICI grant (TTW 16141). The clinical trial was supported in kind by Eurorad S.A. and Hamamatsu Photonics.

**Compliance with ethical standards**

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Conflict of interest** FvL and HvdP received, and PM was supported by a research grant from Intuitive Surgical. HS and LM are employees of Eurorad S.A.

**References**

1. Herrmann K, Nieweg OE, Povoski SP. Radioguided surgery: current applications and innovative directions in clinical practice. Switzerland: Cham: Springer; 2016.

2. Jeschke S, Beri A, Grull M, Ziererhofer J, Prammer P, Leeb K, et al. Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer. Eur Urol. 2008;53:126–32. https://doi.org/10.1016/j.eururo.2007.03.064.

3. Paredes P, Vidal-Sicart S, Campos F, Tapia A, Sanchez N, Martinez S, et al. Role of ICG-99mTc-nanocollod for sentinel lymph node detection in cervical cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2017;44:1853–61. https://doi.org/10.1007/s00259-017-3706-4.

4. van Oosterom MN, Simon H, Mengus L, Welling MM, van der Poel HG, van den Berg NS, et al. Revolutionizing (robot-assisted) laparoscopic gamma tracing using a drop-in gamma probe technology. Am J Nucl Med Mol Imaging. 2016;6:1–17.

5. Kapteijn BA, Nieweg OE, Muller SH, Liem IH, Hoefnagel CA, Rutgers EJ, et al. Validation of gamma probe detection of the sentinel node in melanoma. J Nucl Med Off Pub, Soc Nucl Med. 1997;38:362–6.

6. KleinJan GH, Bunschoten A, van den Berg NS, Olmos RA, Klop WM, Horenbals S, et al. Fluorescence guided surgery and tracer-dose, fact or fiction? Eur J Nucl Med Mol Imaging. 2016;43:1857–67. https://doi.org/10.1007/s00259-016-3372-y.

7. KleinJan GH, van Werkhoven E, van den Berg NS, Karakullukcu MB, Zijlmans H, van der Hage JA, et al. The best of both worlds: a hybrid approach for optimal pre- and intraoperative identification of sentinel lymph nodes. Eur J Nucl Med Mol Imaging. 2018; https://doi.org/10.1007/s00259-018-4028-x.

8. KleinJan GH, van den Berg NS, de Jong J, Wit EM, Thygesen H, Vegt E, et al. Multimodal hybrid imaging agents for sentinel node mapping as a means to (re)connect nuclear medicine to advances made in robot-assisted surgery. Eur J Nucl Med Mol Imaging. 2016;43:1278–87. https://doi.org/10.1007/s00259-015-3292-2.

9. Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480–7. https://doi.org/10.1016/j.eururo.2011.10.044.

10. Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. 99mTechnetium-based prostate-specific membrane antigen–radioguided surgery in recurrent prostate Cancer. Eur Urol. 2018; https://doi.org/10.1016/j.eururo.2018.03.013.